Reuters logo
5 months ago
BRIEF-Lonza and Selecta Biosciences announces manufacturing agreement for Anc80-AAV-based gene therapy
February 16, 2017 / 12:40 PM / 5 months ago

BRIEF-Lonza and Selecta Biosciences announces manufacturing agreement for Anc80-AAV-based gene therapy

1 Min Read

Feb 16 (Reuters) - Lonza Group AG -

* Lonza and Selecta Biosciences announce manufacturing agreement for Anc80-AAV-based gene therapy for treatment of methylmalonic acidemia

* Lonza will produce an Anc80-AAV-Based gene therapy product for proprietary program for treatment of methylmalonic acidemia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below